

R_3 is H, C₁₋₆ alkyl, phenyl, or benzyl;

each of R_5 , R_6 , R_7 and R_8 is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino, with the proviso that R_7 is methyl; one of R_a , R_b , R_c , R_d , and R_e is -WYZ and the others are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;

W is R_9 , $O-R_9$, NR_{10} , $(CO)(O)R_9$, $N(R_{10})SO_2R_9$, $O(CO)R_9$, $(CO)NR_{10}$, or $N(R_{10})CO-R_9$, wherein R_9 is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆ alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R_{10} is H, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclic radical;

Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆ alkoxy;

Z is C₂₋₈ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO₂, wherein G is R_{15} , COR_{15} , $COOR_{15}$, SO_2R_{15} , SO_2N or CSR_{15} ; or Z is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C₁₋₆ alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and C₂₋₅ heterocyclic radical; and R_{15} is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, or C₄₋₇ cycloalkenyl;

provided that where R_6 is $WNR_{11}R_{12}$, each of R_{11} and R_{12} being independently selected from C₁₋₆ alkyl, then at least one of the following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is R_9 , NR_{10} , $(CO)(O)R_9$, $O(CO)R_9$, $(CO)NHR_9$, or $N(R_{10})(CO)R_9$;

and further provided that where each of R_a , R_b , R_d , and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent one carbon-carbon double bond or are absent; or R_7 or R_8 is alkyl, alkoxy, halo, or amino;

and further provided that where each of R_a , R_b , R_d , and R_e is H, and W is a straight chain, unsubstituted propoxy, then YZ is not N-piperidyl or N-morpholinyl; and

each of the above hydrocarbonyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical, phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

2. (currently amended) A compound of claim 1, wherein Z comprises piperidyl, morpholinyl, ~~benzyl-amino, phenyl-amino, substituted benzyl-amino,~~ piperazinyl, pyrrolidyl, or a C₆₋₈ cycloalkylimino radical.

3. (deleted)

3 ~~4~~ (original) A compound of claim 1, wherein W is hydroxy-substituted C₂₋₄ alkoxy, ^{or} C₂₋₄ alkoxy, ~~C₂₋₄ alkyl-amino, butenyl, or butynyl.~~

4 ~~5~~ (currently amended) A compound of claim 1, wherein W comprises propoxy, ^{or} ethoxy, ~~propyl-amino, or ethyl-amino,~~ and one of R_7 and R_8 is methyl.

6. (deleted)

5 ~~7~~ (original) A compound of claim 1 wherein at least one of R_a , R_b , R_d , and R_e is methyl.

6 ~~8~~ (currently amended) A compound of claim 1, wherein each of R_5 , R_6 , R_7 and R_8 is independently H, methyl, ethyl, methoxy, ethoxy, fluoro, or chloro; or wherein one of R_a , R_b , R_c , R_d , and R_e is WZ

and the others are independently selected from H, methyl, ethyl, methoxy, ethoxy, fluoro, or chloro; or both.

7 9. (original) A compound of claim 1, wherein both dashed lines are present to form two carbon-carbon double bonds.

A 2
cost

8 10. (original) A compound of claim 1, wherein both dashed lines are absent.

9 11. (original) A compound of claim 1, wherein R_a or R_e is methyl, fluoro, or methoxy.

10 12. (original) A compound of claim 1, provided that where each of R_a , R_b , R_d , and R_e is H, and W is a straight chain, unsubstituted alkoxy; then at least ^{one} ~~two~~ of the following ^{is} ~~are~~ true: Z is cyclic; at least one of the dashed lines is absent; and R_7 or R_8 is methyl.

B
B

13. (deleted)

11 14. (currently amended) A compound of claim 1, wherein

R_3 is H or methyl;

each of R_b and R_d is independently H, methyl, or methoxy;

each of R_7 and R_8 is independently H, methyl, fluoro, or chloro;

each of R_5 and R_6 is H;

each of R_a or R_e is independently H, methyl, fluoro, or chloro;

W is C₂₋₄ alkoxy, ~~C₄ alkylene, C₄ alkynylene, C₄ alkenylene,~~

~~N(R₁₀)SO₂(C₁₋₃ alkyl), -(CO)O-C₂₋₃ alkyl, -(CO)NH-(C₁₋₃ alkyl), -NH(CO)(C₁₋₃ alkyl), or -NH(C₁₋₆ alkyl);~~ and

Z is pyrrolidyl, piperidyl, morpholinyl, piperazinyl, (piperidyl)-

piperidyl, or NR₁₁R₁₂ where each of R₁₁ and R₁₂ is independently

selected from H, C₄₋₅ alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and

C₂₋₅ heterocyclic radical, but at least one of R₁₁ and R₁₂ is not

H; or taken together, R₁₁ and R₁₂ with the N to which they are

attached form a C₆₋₈ cycloalkylimino radical.

B

A

15. (deleted)

¹²~~16~~. (currently amended) A compound of claim 2, selected from 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-^{hexamethyleneimino}Cycloheptylamino)propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; and 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; and 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

¹³~~17~~. (currently amended) A compound of ~~claim 2~~, selected from N,N-Diethyl-N'-[4-(7-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; and 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; and N,N-Diethyl-N'-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine.

¹⁴~~18~~. (original) A compound of claim ¹²~~16~~, having the formula 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

¹⁵~~19~~. (currently amended) A pharmaceutical composition comprising a compound of formula claim 1 (I) and a pharmaceutically-acceptable carrier.

¹⁶~~20~~. (currently amended) A pharmaceutical composition of claim ¹⁵~~19~~, wherein said compound has a formula wherein R₃ is H or methyl; each of R_b and R_d is independently H, methyl, or methoxy; each of R₇ and R₈ is independently H, methyl, fluoro,

or chloro; each of R_5 and R_6 is H; each of R_a or R_e is independently H, methyl, fluoro, or chloro; W is C_{2-4} alkoxy, C_4 alkylene, C_4 -alkynylene, C_4 -alkenylene, ~~$(CO)O-C_{2-3}$ -alkyl, $N(R_{10})SO_2R_9$, $(CO)NH-(C_{1-3})$ -alkyl, $NH(CO)(C_{1-3})$ -alkyl, or $NH(C_{1-6})$ -alkyl~~; and Z is pyrrolidyl, piperidyl, morpholinyl, piperazinyl, (piperidyl)-piperidyl, or $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C_{1-5} -alkyl, phenyl, benzyl, C_{3-8} -cycloalkyl, and C_{2-5} heterocyclic radical, but at least one of R_{11} and R_{12} is not H; or taken together, R_{11} and R_{12} with the N to which they are attached form a C_{6-8} -cycloalkylimino radical.


17 ~~21.~~ (currently amended) A pharmaceutical composition of claim ~~20,~~ ¹⁶ wherein said compound has a formula selected from 2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-hexamethyleneimino-cycloheptylamino)propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; and 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-

5,6,7,8-tetrahydroimidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydroimidazo[1,2-a]pyridine; and N,N-Diethyl-N'-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine.

A-2
C or

¹⁸
-22. (original) A pharmaceutical composition of claim ¹⁶20, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

¹⁹
-23. (currently amended) A method for treating disorders mediated by the histamine H₃ receptor in a patient, said method comprising administering to the patient a pharmaceutically effective amount of compound of formula (I):



^B
^B
independently each ^{completes} wherein both dashed lines are a carbon-carbon double bond, or both are absent;

R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl;

each of R₅, R₆, R₇ and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino;

^{B2}
one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;

W is ~~R₉-O-R₉, NR₁₀, (CO)(O)R₉, N(R₁₀)SO₂-R₉, O(CO)R₉, (CO)NR₁₀, or N(R₁₀)-CO-R₉~~, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆ alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and ~~R₁₀ is H, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclic radical;~~

Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆ alkoxy;
 Z is C₂₋₈ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅, SO₂R₁₅, SO₂N or CSR₁₅; ~~or Z is NR₁₁R₁₂, where each of R₁₁ and R₁₂ is independently selected from H, C₁₋₆ alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and C₂₋₅ heterocyclic radical; and R₁₅ is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, or C₄₋₇ cycloalkenyl;~~

~~provided that where R₆ is WNR₁₁R₁₂, each of R₁₁ and R₁₂ being independently selected from C₁₋₆ alkyl, then at least one of the following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is R₉, NR₁₀, (CO)(O)R₉, O(CO)R₉, (CO)NHR₉, or N(R₁₀)(CO)R₉;~~

~~and further provided that where each of R_a, R_b, R_d, and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent one carbon-carbon double bond or are absent; or R₇ or R₈ is alkyl, alkoxy, halo, or amino; and~~


each of the above hydrocarbonyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical, phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;
 or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

20
 24. (currently amended) A method of claim ¹⁹23, wherein said compound is selected from 2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine;

(E/Z) 2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl-(2-pyrrolidin-1-yl-ethyl)-amine; 4-(8-Methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Cycloheptylamino-propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methyl-imidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine; 2-(4-piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

21 ¹⁹
~~25~~ (original) A method of claim ~~23~~, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

22
~~26~~ (currently amended) A method for treating a patient with a central nervous system disorder, said method comprising administering to the patient a pharmaceutically-effective amount of a compound of formula (I):



B A 2
B cort

B2

independently each completes
 wherein ~~both~~ dashed lines ~~are~~ a carbon-carbon double bond, or
~~both~~ are absent;

R₃ is H, C₁₋₆ alkyl, phenyl, or benzyl;

each of R₅, R₆, R₇ and R₈ is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino;

one of R_a, R_b, R_c, R_d, and R_e is -WYZ and the others are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;

W is O-R₉, wherein R₉ is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆ alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R₁₀ is H, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclic radical;

Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆ alkoxy;

Z is C₂₋₈ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO₂, wherein G is R₁₅, COR₁₅, COOR₁₅, SO₂R₁₅, SO₂N or CSR₁₅; and R₁₅ is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, or C₄₋₇ cycloalkenyl;

and

each of the above hydrocarbyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C₁₋₃ alkyl, halo, hydroxy, C₂₋₅ heterocyclic radical, phenyl, and phenyl(C₁₋₃ alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom;

or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

27. (deleted)

²³
28. (original) A method of claim ²²26, wherein said central nervous system disorder is selected from sleep/wake disorders, arousal/vigilance disorders, dementia, Alzheimer's disease, epilepsy, narcolepsy, eating disorders, motion sickness, vertigo, attention deficit hyperactivity disorder, learning and memory disorders, mild cognitive impairment, and schizophrenia.

²⁴
29. (original) A method of claim ²²26, wherein said central nervous system disorder is selected from Alzheimer's disease, epilepsy, eating disorders, learning and memory disorders, migraine, sleep/wake disorders, allergic rhinitis, schizophrenia, mild cognitive impairment, and asthma.


²⁵
30. (currently amended) A method of claim ²²26, wherein said compound is selected from 2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine; (E/Z)-2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-hexamethyleneimino-cycloheptylamino)propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-

methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine; 2-(4-piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

²⁶
31. (original) A method of claim ²²~~26~~²⁷, wherein said compound is 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.

²⁷
32. (original) A method of claim ²²~~26~~, wherein said disorder is selected from sleep/wake disorders, arousal/vigilance disorders, attention deficit hyperactivity disorder, and learning and memory disorders.

²⁸
33. (currently amended) A method for treating a patient with an upper airway allergic response, said method comprising administering to the patient a pharmaceutically-effective amount of a compound of formula (I):



independently each

completes

wherein ~~both~~ ^{is} ~~dashed lines~~ ^{are} a carbon-carbon double bond, or both ^{are} absent;

R_3 is H, C₁₋₆ alkyl, phenyl, or benzyl;

each of R_5 , R_6 , R_7 and R_8 is independently H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, or amino;

one of R_a , R_b , R_c , R_d , and R_e is -WYZ and the others are independently selected from H, C₁₋₆ alkyl, C₁₋₆ alkoxy, halo, and amino;

W is R_9 , $O-R_9$, NR_{10} , $(CO)(O)R_9$, $N(R_{10})SO_2R_9$, $O(CO)R_9$, $(CO)NR_{10}$, or $N(R_{10})CO-R_9$, wherein R_9 is C₁₋₆ alkylene, C₂₋₆ alkynylene, C₂₋₆ alkenylene, phenylene, or C₂₋₅ heterocyclic bivalent radical, and R_{10} is H, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, phenyl, or C₂₋₅ heterocyclic radical;

Y is absent, C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, or C₁₋₆ alkoxy;

Z is C₂₋₈ heterocyclic radical with at least one basic nitrogen atom in the ring, optionally including in the ring up to 3 additional heteroatoms or moieties independently selected from O, C=O, N, NH, NG, S, SO, and SO₂, wherein G is R_{15} , COR_{15} , $COOR_{15}$, SO_2R_{15} , SO_2N or CSR_{15} ; or Z is $NR_{11}R_{12}$ where each of R_{11} and R_{12} is independently selected from H, C₁₋₆ alkyl, phenyl, benzyl, C₃₋₈ cycloalkyl, and C₂₋₅ heterocyclic radical; and R_{15} is C₁₋₆ alkyl, C₂₋₆ alkynyl, C₂₋₆ alkenyl, C₃₋₇ cycloalkyl, or C₄₋₇ cycloalkenyl;

provided that where R_c is $WNR_{11}R_{12}$, each of R_{11} and R_{12} being independently selected from C₁₋₆ alkyl, then at least one of the following is true: R_b or R_d is alkyl, alkoxy, amino, or halo; the dashed lines represent one carbon-carbon double bond or are absent; R_a or R_e is alkyl, alkoxy, amino, or halo; or W is R_9 , NR_{10} , $(CO)(O)R_9$, $O(CO)R_9$, $(CO)NHR_9$, or $N(R_{10})(CO)R_9$;

and further provided that where each of R_a , R_b , R_d , and R_e is H, and W is a straight chain, unsubstituted alkoxy, then at least one of the following is true: Z is cyclic; the dashed lines represent

one carbon-carbon double bond or are absent; or R_7 or R_8 is alkyl, alkoxy, halo, or amino; and each of the above hydrocarbonyl or heterocyclic groups being optionally substituted with between 1 and 3 substituents selected from C_{1-3} alkyl, halo, hydroxy, C_{2-5} heterocyclic radical, phenyl, and phenyl(C_{1-3} alkyl); and wherein each of the above heterocyclic groups may be attached to the rest of the molecule by a carbon atom or a heteroatom; or a pharmaceutically acceptable salt, amide, ester, or hydrate thereof.

A-2

cut

29

28

34. (currently amended) A method of claim 33, wherein said compound

is selected from 2-[4-[3-(Piperidino)propylamino]phenyl]-7-methylimidazo[1,2-a]pyridine; (E/Z) 2-[4-[4-Piperidinobut-1-enyl]phenyl]-7-methylimidazo[1,2-a]pyridine; [4-(8-Methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-pyrrolidin-1-yl-ethyl)-amine; [4-(8-Methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-(2-piperidin-1-yl-ethyl)-amine; 2-[4-[4-Pyrrolidinobutyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-[4-[2-(1-Methyl)-2-pyrrolidino]ethoxy-3-methylphenyl]imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-(4-Piperidinopropoxy-2-methylphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-hexamethyleneimino-cycloheptylamino)propoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-[4-Piperidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Pyrrolidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-imidazo[1,2-a]pyridine; 2-[4-[4-Pyrrolidinobut-1-ynyl]phenyl]-7-methylimidazo[1,2-a]pyridine; 2-(4-Piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(7-methylimidazo[1,2-a]pyridin-2-yl)-phenyl]-propane-1,3-diamine; 2-[4-(3-Piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-imidazo[1,2-a]pyridine; 7-methyl-2-[2-methyl-

hexamethyleneimino
cycloheptylamino

4-(3-piperidin-1-yl-propoxy)-phenyl]-5,6,7,8-tetrahydro-
imidazo[1,2-a]pyridine; N,N-Diethyl-N'-[4-(8-methylimidazo[1,2-
a]pyridin-2-yl)-phenyl]-ethane-1,2-diamine; 2-(4-
piperidinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine; and 2-
(4-morpholinopropoxyphenyl)-8-methylimidazo[1,2-a]pyridine.

h2

carb.

³⁰ 35. (original) A method of claim ²⁸ 33, wherein said compound is 2-(4-
Piperidinopropoxyphenyl)-7-methylimidazo[1,2-a]pyridine.